Iomedico (Germany)

Recent papers from Iomedico (Germany)

1. Final results of the CARO study: real-world adherence, effectiveness and patient-reported quality of life with carfilzomib-based regimens in German patients with relapsed/refractory multiple myelomaAnnals of Hematology · 2026
2. Prospective, longitudinal oncology registries enabling advanced real-world evidence: the iOMEDICO experienceESMO Real World Data and Digital Oncology · 2026
3. Real-World Evidence for Oncology Patients With Rare NTRK Gene Fusions: Final Results From the German Multicenter Patient Cohort Study REALTRKJCO Precision Oncology · 2026
4. Durvalumab Consolidation After Definitive Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Cohort Analysis from the German Prospective, Observational CRISP Registry (AIO-TRK-0315)Cancers · 2026
5. Unlocking In-Context Learning for Natural Datasets Across ModalitiesInternational Journal of Computer Vision · 2026
6. Effectiveness outcomes by treatment-free interval among patients receiving palbociclib plus endocrine therapy in HR+/HER2− advanced breast cancer in the real-world setting: Results from the PERFORM study.Journal of Clinical Oncology · 2026
7. 462P Real-world effectiveness of 2nd-line treatments following 1L palbociclib + endocrine therapy: Preliminary results from the non-interventional study PERFORMESMO Open · 2026
8. Unmet need for patients with metastatic triple-negative breast cancer initiating first-line treatment: data from the prospective German tumor registry OPALESMO Real World Data and Digital Oncology · 2026
9. Lenalidomide Plus Dexamethasone as FIRST‐Line Therapy in Transplant‐Ineligible Patients With Multiple Myeloma: Final Results of the Prospective, Non‐Interventional Study FIRST ‐ NIS and Comparison With the FIRST Pivotal Phase III Clinical TrialCancer Medicine · 2026
10. Prediction of the individual risk for the development of brain metastases in patients with non‐oncogene‐addicted non‐small cell lung cancer: Real‐world data from the German prospective CRISP registry ( AIO ‐ TRK ‐0315)International Journal of Cancer · 2026
11. Prediction of dose reductions and impact of reduced starting doses of CDK4 /6i on effectiveness in HR ‐positive/ HER2 ‐negative metastatic breast cancer: Real‐world data from the OPAL registryInternational Journal of Cancer · 2026
12. Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315)European Journal of Cancer · 2026
13. Treatment and outcomes of patients with HR+/HER2− early breast cancer in a real-world setting in GermanyCancer Treatment and Research Communications · 2026
14. Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine careESMO Real World Data and Digital Oncology · 2026
15. Real-world incidence of bleeding events in patients with chronic lymphocytic leukemia treated with acalabrutinib +/- obinutuzumab and requiring direct oral anticoagulationBlood · 2025
16. Head‐to‐head comparison of TKI and CPI first‐line treatment strategies in advanced renal cell carcinoma—Real‐world data from the German research platform CARATInternational Journal of Cancer · 2025
17. Eucalyptus Leaf Extract With Oenothein B Reduces Sugar‐Induced Hepatic and Visceral Fat in Adult Japanese Men: A Randomized StudyHepatology Research · 2025
18. Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE.2025
19. Transcription of Handwritten Forms for Medical Study Documentation2025
20. Long-term survival in patients with pancreatic cancer treated with second-line liposomal irinotecan plus 5-fluorouracil/leucovorin: observations from Korea, Italy, and GermanyESMO Gastrointestinal Oncology · 2025